NATCO Pharma Limited, at its board meeting, held on February 14, 2022, Sri Sridhar Sankararaman, Non-Executive Non Independent Director of the Company has resigned from the Directorship of the company with effect from 15th February, 2022 due to his professional obligations and other pre occupations. The company also announced the re-constitution of audit Nomination and Remuneration committee as: Sri T. V. Rao, Independent Director.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
982.9 INR | -0.71% | -0.21% | +21.14% |
May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.14% | 2.12B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- NATCOPHARM Stock
- News NATCO Pharma Limited
- NATCO Pharma Limited Announces Board Changes